{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-21-012080","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.671910+00:00","generated_at":"2026-06-28T09:17:27.019614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Zomedica Q3 net loss $6.3M; revenue minimal from TRUFORMA launch; cash $271.4M","bullets":["Net loss of $6.3M ($0.01/share) vs $5.0M loss in Q3 2020; nine-month loss $15.1M.","Revenue from TRUFORMA products was $22,514; commercial launch began March 2021.","Cash and equivalents $271.4M at Sept 30, 2021; pro forma after PulseVet acquisition ~$199.5M.","SG&A expense rose 166% to $6.1M, driven by share-based compensation and PulseVet deal costs.","R&D expense fell 89% to $0.3M as initial TRUFORMA assays completed; development shifts to commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-21-012080","json":"https://secwatch.observer/filing/0001654954-21-012080.json","markdown":"https://secwatch.observer/filing/0001654954-21-012080.md","text":"https://secwatch.observer/filing/0001654954-21-012080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495421012080/0001654954-21-012080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495421012080/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:17:27.019614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}